MAM
Online advertising in the US will reach $11 billion this year
MUMBAI: The internet in the US is increasingly becoming a useful platform for marketers to reach consumers. eMarketer reports that while paid search advertising will grow 22.5 per cent in 2005, spending on non-search advertising, including rich media, online display ads and sponsorships, will rise by 20 per cent.
In total, online advertising will reach $11.3 billion in 2005. Ford’s Lincoln Mercury division is putting 25 per cent of its 2005 marketing budget online, and Vonage spends over 50 per cent of its marketing dollars on the Internet. In order to help companies understand better how they can leverage the online medium as an advertising and marketing tool Strategic Research Institute and eMarketer will conduct the eMarketing 2005 forum in Orlando, Florida on 19 and 20 May 2005.
At the forum companies representing a wide variety of categories will seek to advance their online marketing strategies. They include GlaxoSmithKline, Johnson & Johnson, Toyota Motor Sales, Hewlett Packard and AOL Media Works. The forum will uncover the latest trends and techniques in online marketing strategies.
In the sesion titled The Big Picture eMarketer CEO Geoffrey Ramsey will cut through the hype, misinformation and contradictory research data to provide a big picture view of where online marketing is today, and where it’s going in the near future. Drawing upon aggregated data from dozens of leading research firms, and pulling no punches, Geoffrey will walk attendees the stats and trends you need to know, including online demographics and usage patterns, Internet shopping and buying, the growing adoption of broadband and wireless technologies and the Internet’s unique and increasingly powerful role in the marketing mix.
Hewlett-Packard VP Interactive Communications – Global Brand Advertising Mary Bermel will deliver another keynote address. When the consumer is in charge how do marketers seize new opportunities in online marketing. New technologies clearly pose increased challenges to marketers. The “digital revolution” demands increased creativity in connecting with customers. Bermel will dwell on how brands are discovering new tools and strategies to come closer to their customers.
The Internet has heightened choices for the customer and has empowered them with lots of new choices. The challnge for marketers is keeping up with the new demands on product choices, retail options, marketing and media preferences and brand-building.
Another session will predict online ad spending growth, overall and by the specific ad format. It will look at the strategies and techniques that successful advertisers using to fully exploit the interactive channel as well as the mistakes they are avoiding.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
